Targeting brain lipid homeostasis to treat Alzheimer's disease

点击翻译按钮获取中文摘要

Dementia affects approximately 250,000 people in Australia at an estimated cost (in 2002) of $6.6 billion per annum. The major cause of dementia (accounting for approximately 70% of all cases) is Alzheimer's disease (AD); a progressive neurodegenerative illness for which there is no curative or disease-stalling treatment. Due to increases in life expectancy, the incidence of AD is predicted to triple by 2050 unless disease-modifying treatments are developed. This research program will provide novel realistic pharmaceutical approaches to treat AD. Even if the onset of AD could be delayed by a few years the personal and financial benefits would be enormous. The potential for this research to generate commercially viable Australian intellectual property is also significant.